ArticleInternational journal of nanomedicine
Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin.
Article in International journal of nanomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 43 citations in OpenAlex.
- Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis.Journal of pharmaceutical analysis · 2025Article
- Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy.International journal of pharmaceutics · 2023Review
- Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin.International journal of nanomedicine · 2022Review
- Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.International journal of molecular sciences · 2020Article
- Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy.Drug delivery · 2019Article
- High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.ACS nano · 2019Article
- Dual-modified natural high density lipoprotein particles for systemic glioma-targeting drug delivery.Drug delivery · 2018Article
- Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.Surgery · 2018Article
- Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.Science advances · 2018Article
- Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery.Drug delivery · 2017Review
- Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The purpose of this study was to develop a novel synthetic high-density lipoprotein (sHDL) nanoparticle delivery system for 10-hydroxycamptothecin (HCPT) for treatment of colon carcinoma. HDL is recognized by scavenger receptor B-I (SR-BI) over-expressed in colon carcinomas 5- to 35-fold relative to the human fibroblasts. The sHDL nanoparticles were composed of apolipoprotein A-I mimic peptide (5A) and contained 0.5%-1.5% (w/w) of HCPT. An optimized HCPT-sHDL formulation exhibited 0.7% HCPT loading with 70% efficiency with an average size of 10-12 nm. Partitioning of HCPT in the sHDL lipid membrane enhanced drug stability in its active lactone form, increased solubilization, and enabled slow release. Cytotoxicity studies in HT29 colon carcinoma cells revealed that the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.